Anonymous
Guest
Anonymous
Guest
Is he coming to Dendreon?
San Francisco Business Times
Reiner Laus, president of Bavarian Nordic A/S's cancer vaccines division and head of BN ImmunoTherapeutics in Mountain View, left the company Tuesday during an ongoing late-stage trial of its experimental prostate cancer vaccine.
The Denmark-based parent company did not provide more details about the circumstances that led to Laus' departure. It said the search for his replacement is expected to conclude soon.
Laus, who was the fourth employee at Dendreon Corp. (NASDAQ: DNDN), the Seattle developer of the Provenge prostate cancer vaccine, had headed BN ImmunoTherapeutics since 2005. He helped develop the company's clinical pipeline, most significantly Prostvac, which is in a Phase III trial in prostate cancer.
BN started its 1,200-patient Phase III trial in November 2011. The study is expected to fully enroll by the end of 2013. Data would read out in late 2015.
San Francisco Business Times
Reiner Laus, president of Bavarian Nordic A/S's cancer vaccines division and head of BN ImmunoTherapeutics in Mountain View, left the company Tuesday during an ongoing late-stage trial of its experimental prostate cancer vaccine.
The Denmark-based parent company did not provide more details about the circumstances that led to Laus' departure. It said the search for his replacement is expected to conclude soon.
Laus, who was the fourth employee at Dendreon Corp. (NASDAQ: DNDN), the Seattle developer of the Provenge prostate cancer vaccine, had headed BN ImmunoTherapeutics since 2005. He helped develop the company's clinical pipeline, most significantly Prostvac, which is in a Phase III trial in prostate cancer.
BN started its 1,200-patient Phase III trial in November 2011. The study is expected to fully enroll by the end of 2013. Data would read out in late 2015.